No Data
Rapport Therapeutics, Inc. (RAPP) Receives a Buy From TD Cowen
Rapport Therapeutics' Promising Trial Results and Leadership Change
Stifel Maintains Rapport Therapeutics(RAPP.US) With Buy Rating
Stifel Nicolaus Remains a Buy on Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics Reports Positive Early Data for Epilepsy Drug Candidate
Express News | Rapport Therapeutics' Positron Emission Tomography Trial And Second Multiple Ascending Dose Trial For RAP-219, Demonstrated RAP-219 Achieved Target Receptor Occupancy Associated With Maximal Efficacy In Prior Preclinical Models Within Five Days Of...